OverviewSuggest Edit

ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, that is in a clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in a clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.

TypePublic
Founded1981
HQWaltham, MA, US
Websiteimmunogen.com
Employee Ratings3.3
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2020)79(+6%)
Job Openings12
Revenue (FY, 2020)$132.3 M(+61%)
Share Price (Nov 2021)$5.7(+2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ImmunoGen

Mark Enyedy

Mark Enyedy

President and Chief Executive Officer, Director
Audrey Bergan

Audrey Bergan

Senior Vice President and Chief Human Resources Officer
Susan Altschuller

Susan Altschuller

Senior Vice President and Chief Financial Officer
Joe Kenny

Joe Kenny

Vice President, Acting General Counsel and Intellectual Property
Stacy Coen

Stacy Coen

Senior Vice President, Chief Business Officer
Anna Berkenblit

Anna Berkenblit

Senior Vice President, Chief Medical Officer
Show more

ImmunoGen Office Locations

ImmunoGen has an office in Waltham
Waltham, MA, US (HQ)
830 Winter St
Show all (1)

ImmunoGen Financials and Metrics

ImmunoGen Revenue

ImmunoGen's revenue was reported to be $132.3 m in FY, 2020 which is a 60.8% increase from the previous period.
USD

Revenue (Q1, 2021)

15.7m

Net income (Q1, 2021)

(34.1m)

EBIT (Q1, 2021)

(28.9m)

Market capitalization (12-Nov-2021)

1.1b

Closing stock price (12-Nov-2021)

5.7

Cash (31-Mar-2021)

283.1m

EV

882.8m
ImmunoGen's current market capitalization is $1.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

53.4m82.3m132.3m

Revenue growth, %

54%61%

General and administrative expense

36.7m38.5m38.6m

R&D expense

174.5m114.5m114.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

8.6m15.5m13.3m13.3m15.0m18.2m15.7m

General and administrative expense

10.8m8.7m9.2m8.9m9.8m10.2m10.2m

R&D expense

38.9m28.6m21.0m27.4m22.9m24.7m34.4m

Operating expense total

50.2m56.6m31.2m37.1m33.4m34.9m44.6m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

262.3m176.2m293.9m

Accounts Receivable

1.7m7.5m35.0k

Prepaid Expenses

4.5m5.4m7.9m

Current Assets

278.8m208.9m324.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

270.4m239.8m204.5m247.3m219.5m188.2m283.1m

Accounts Receivable

233.0k94.0k54.0k313.0k5.1m93.0k

Prepaid Expenses

6.7m6.6m5.0m7.7m6.4m7.9m15.4m

Current Assets

289.8m259.4m225.7m270.7m241.4m219.3m319.6m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(168.8m)(104.1m)(44.4m)

Depreciation and Amortization

7.4m4.0m2.1m

Inventories

1.0m

Accounts Payable

2.7m(1.0m)(819.0k)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(43.8m)(87.2m)(108.9m)(29.1m)(53.4m)(75.8m)(34.1m)

Depreciation and Amortization

1.2m2.4m3.3m529.0k1.0m1.6m551.0k

Accounts Payable

(2.7m)(3.2m)(3.8m)(649.0k)2.2m(1.0m)3.8m

Cash From Operating Activities

10.2m(20.8m)(55.8m)(28.3m)(56.5m)(87.2m)(44.6m)
USDFY, 2018

EV/EBIT

-2.8 x

EV/CFO

-2.7 x

Revenue/Employee

180.6k

Debt/Equity

0.2 x

Financial Leverage

26.9 x

P/E Ratio

(4.0)
Show all financial metrics

ImmunoGen Operating Metrics

FY, 2018FY, 2019FY, 2020

Patent Applications

600650600

Patents Issued

1 k1.3 k1.4 k
Show all operating metrics

ImmunoGen Acquisitions / Subsidiaries

Company NameDateDeal Size
Hurricane, LLC
ImmunoGen BioPharma (Ireland) Limited
ImmunoGen Europe Limited
ImmunoGen Securities Corp.

ImmunoGen Revenue Breakdown

Embed Graph

ImmunoGen revenue breakdown by business segment: 48.2% from License and Milestone Fees, 51.8% from Non-Cash Royalty Revenue and 0.0% from Other

ImmunoGen Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

ImmunoGen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ImmunoGen Online and Social Media Presence

Embed Graph

ImmunoGen Company Culture

  • Overall Culture

    B+

    74/100

  • CEO Rating

    A+

    85/100

  • Compensation

    C-

    63/100

Learn more on Comparably

ImmunoGen News and Updates

Insights on the Next Generation Biological Drugs Global Market to 2027 - Featuring AstraZeneca, Seattle Genetics and ImmunoGen Among Others

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- The "Next Generation Biological Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering. The report on the global next generation biological drugs market...

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

ImmunoGen Inc. today announced that the Company will host a conference call.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Inc. (Nasdaq: IMGN) today announced that on June 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,900 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Inc…

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Inc. (Nasdaq: IMGN) announced that on June 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,900 shares of its common stock to four employees under the ImmunoGen, Inc. Inducement Equity Incentiv…

ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

ImmunoGen announced mature data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate

ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

ImmunoGen reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2021
Show more

ImmunoGen Blogs

Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum Agnostic Ovarian Cancer: Final Analysis

The post Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum Agnostic Ovarian Cancer: Final Analysis appeared first on ImmunoGen.

IMGC936, an Investigational ADAM9-Targeting Antibody-Drug Conjugate, is Active Against Patient-Derived ADAM9-Expressing Xenograft Models

The post IMGC936, an Investigational ADAM9-Targeting Antibody-Drug Conjugate, is Active Against Patient-Derived ADAM9-Expressing Xenograft Models appeared first on ImmunoGen.

ImmunoGen Frequently Asked Questions

  • When was ImmunoGen founded?

    ImmunoGen was founded in 1981.

  • Who are ImmunoGen key executives?

    ImmunoGen's key executives are Mark Enyedy, Audrey Bergan and Susan Altschuller.

  • How many employees does ImmunoGen have?

    ImmunoGen has 79 employees.

  • What is ImmunoGen revenue?

    Latest ImmunoGen annual revenue is $132.3 m.

  • What is ImmunoGen revenue per employee?

    Latest ImmunoGen revenue per employee is $1.7 m.

  • Who are ImmunoGen competitors?

    Competitors of ImmunoGen include Puma Biotechnology, Ablynx and ADC Therapeutics.

  • Where is ImmunoGen headquarters?

    ImmunoGen headquarters is located at 830 Winter St, Waltham.

  • Where are ImmunoGen offices?

    ImmunoGen has an office in Waltham.

  • How many offices does ImmunoGen have?

    ImmunoGen has 1 office.